12 news items
Anavex Life Sciences to Present at the H.C. Wainwright 2nd BioConnect Investor Conference at NASDAQ
AVXL
14 May 24
in pediatric patients with Rett syndrome. ANAVEX®2-73 is an orally available drug candidate that restores cellular homeostasis by targeting
HC Wainwright & Co. Reiterates Buy on Anavex Life Sciences, Maintains $40 Price Target
AVXL
10 May 24
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Anavex Life Sciences (NASDAQ:AVXL) with a Buy and maintains $40 price target.
Anavex Life Sciences Reports Fiscal 2024 Second Quarter Financial Results and Provides Business Update
AVXL
9 May 24
in pediatric patients with Rett syndrome. ANAVEX®2-73 is an orally available drug candidate that restores cellular homeostasis by targeting
Anavex Life Sciences to Announce Fiscal 2024 Second Quarter Financial Results on Thursday, May 9th, 2024
AVXL
2 May 24
cellular homeostasis by targeting SIGMAR1 and muscarinic receptors. Preclinical studies demonstrated its potential to halt and/or reverse the course
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Ventyx, Anavex, and Checkpoint and Encourages Investors to Contact the Firm
AVXL
CKPT
VTYX
20 Apr 24
, the Company disclosed that "[a]lthough the trial achieved its primary endpoint, the magnitude of efficacy observed did not meet our internal target
lzkfruwd3wfpoqoe8e2sq3k8itaqvpzicjzj6qcgpxbdhkkyz9ob7wdlmm4
AVXL
CKPT
SOND
16 Apr 24
that "[a]lthough the trial achieved its primary endpoint, the magnitude of efficacy observed did not meet our internal target to support the advancement
wjw8lg8ydf32gowty09
AVXL
CKPT
VTYX
12 Apr 24
target to support the advancement of VTX958 in plaque psoriasis." Based on these results, the Company announced that it "will terminate
9lhjdq0g9201rikcob3rag95m7p1vzsbbb748ryiqr3xpunbfqg
AVXL
11 Apr 24
cellular homeostasis by targeting SIGMAR1 and muscarinic receptors. Preclinical studies demonstrated its potential to halt and/or reverse the course
ywq0rxa8d5s4x6edc86l8c6v3b65v4nc57zlsva77yuwtdvap64g xnveew6
AVXL
VTYX
8 Apr 24
not meet our internal target to support the advancement of VTX958 in plaque psoriasis." Based on these results, the Company announced
xt2m3dl503fpspjvh uo1e
AVXL
HUT
VTYX
4 Apr 24
that "[a]lthough the trial achieved its primary endpoint, the magnitude of efficacy observed did not meet our internal target to support the advancement
nal13drat54b7dyq8e2jxsdoz
AVXL
25 Mar 24
cellular homeostasis by targeting SIGMAR1 and muscarinic receptors. Preclinical studies demonstrated its potential to halt and/or reverse the course
gspmlizbxd49ddmysudkdb24hv7muse9 ux13an
AVXL
18 Mar 24
homeostasis observed in individuals with schizophrenia, upstream of the targets leveraged by standard of care medications. Preceding
- Prev
- 1
- Next